CytomX Therapeutics, Inc.CTMXNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank33
3Y CAGR-55.8%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-55.8%/yr
vs -25.7%/yr prior
Acceleration
-30.2pp
Decelerating
Percentile
P33
Within normal range
vs 3Y Ago
0.1x
Contraction
Streak
2 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2025 | 0.81% |
| 2024 | -0.97% |
| 2023 | -29.94% |
| 2022 | 9.42% |
| 2021 | 8.68% |
| 2020 | -2.00% |
| 2019 | 9.71% |
| 2018 | 30.87% |
| 2017 | 28.84% |
| 2016 | 58.26% |